Prostate cancer remains the second leading cause of cancer death in men in the Western world.
Yet current therapies do not significantly improve the long-term survival of patients with distant metastasis. In this study, we investigated the role of the guanine nucleotide exchange factor Vav3 in prostate cancer progression and metastasis and found that Vav3 expression correlated positively with prostate cancer cell migration and invasion. Stimulation of the receptor tyrosine kinase EphA2 by ephrinA1 resulted in recruitment and tyrosine phosphorylation of Vav3, leading to Rac1 activation as well as increased migration and invasion in vitro. Reduction of Vav3 resulted in fewer para-aortic lymph nodes and bone metastasis in vivo. Clinically, expression of Vav3 and EphA2 was elevated in late-stage and metastatic prostate cancers. Among patients with stage IIB or earlier prostate cancer, higher Vav3 expression correlated with lower cumulative biochemical failure-free survival, suggesting that Vav3 may represent a prognostic marker for posttreatment recurrence of prostate cancer. Together, our findings provide evidence that the Vav3-mediated signaling pathway may serve as a therapeutic target for prostate cancer metastasis.
Written by:
Lin KT, Gong J, Li CF, Jang TH, Chen WL, Chen HJ, Wang LH. Are you the author?
Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli County, Taiwan.
Reference: Cancer Res. 2012 Jun 15;72(12):3000-9.
doi: 10.1158/0008-5472.CAN-11-2502
PubMed Abstract
PMID: 22659453
UroToday.com Investigative Urology Section
